Compare IDXX & MDLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | MDLN |
|---|---|---|
| Founded | 1983 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 37.4B |
| IPO Year | 1996 | 2025 |
| Metric | IDXX | MDLN |
|---|---|---|
| Price | $559.51 | $34.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 23 |
| Target Price | ★ $721.67 | $50.48 |
| AVG Volume (30 Days) | 612.4K | ★ 7.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 7.74 | 0.23 |
| Revenue | $4,303,702,000.00 | ★ $28,432,000,000.00 |
| Revenue This Year | $10.88 | $10.88 |
| Revenue Next Year | $8.59 | $7.69 |
| P/E Ratio | ★ $71.95 | $148.96 |
| Revenue Growth | 10.42 | ★ 11.47 |
| 52 Week Low | $518.55 | $32.49 |
| 52 Week High | $769.98 | $50.88 |
| Indicator | IDXX | MDLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 43.08 |
| Support Level | $536.34 | $33.52 |
| Resistance Level | $583.93 | $43.31 |
| Average True Range (ATR) | 17.11 | 1.60 |
| MACD | -2.68 | -0.17 |
| Stochastic Oscillator | 30.11 | 39.22 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Medline is the largest medical-surgical products and supply chain solutions provider in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.